OPEN END-TURBO-OPTIONSSCHEIN - INCYTE CO.

OPEN END-TURBO-OPTIONSSCHEIN - INCYTE CO. Share Price

DE000HS2DCZ3

Market Closed - BOERSE MUENCHEN 20:36:47 31/05/2024 BST
1.57 ^EUR	+0.64%

3 months	-11.80%
6 months	+11.35%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart INCYTE CORPORATION

Chart OPEN END-TURBO-OPTIONSSCHEIN - INCYTE CO.

Latest news about INCYTE CORPORATION

Incyte Completes Acquisition of Escient Pharmaceuticals	05-30	BU
Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	05-23	MT
Incyte Acquires 2 Office Buildings in Delaware	05-21	MT
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings	05-21	BU

More news

Quotes 5-day view

Date	Price	Change
31/05/24	1.57	+0.64%
30/05/24	1.56	+2.63%
29/05/24	1.52	-.--%
28/05/24	1.52	-3.18%
27/05/24	1.57	-.--%

Real-time BOERSE MUENCHEN

Last update May 31, 2024 at 08:36 pm

More quotes

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	CALL
Underlying	INCYTE CORPORATION
Issuer	HSBC
WKN	HS2DCZ
ISIN	DE000HS2DCZ3
Date issued	25/09/2023
Strike	40.79 $
Maturity	Unlimited
Parity	10 : 1
Emission price	2 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.55 €
Lowest since issue	0.99 €

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

More about the company

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Incyte Corporation

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.79 USD

Average target price

72.8 USD

Spread / Average Target

+25.97%

Consensus